Who owns Royalty Pharma plc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RPRX from SEC Form 13F filings across 647 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 647 institutions disclosed 367.0M shares of Royalty Pharma plc worth $20.56B — about 82.5% of shares outstanding; the largest disclosed holder is MORGAN STANLEY. Source: SEC Form 13F filings, parsed by EvidInvest.
647
13F holders
$20.56B
value, 2026 filers
82.5%
of shares outstanding (367.0M sh)
114
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RPRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 42.9M | $2.41B | 0.1% | 9.6% | -1.5% |
| 2 | Capital International Investors | 35.3M | $1.98B | 0.4% | 7.9% | +0.8% |
| 3 | BlackRock, Inc. | 27.8M | $1.56B | 0.0% | 6.3% | +7.4% |
| 4 | FMR LLC | 24.5M | $1.37B | 0.1% | 5.5% | -2.5% |
| 5 | STATE STREET CORP | 12.3M | $691.8M | 0.0% | 2.8% | +12.3% |
| 6 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.2M | $627.6M | 0.1% | 2.5% | +478.7% |
| 7 | Swedbank AB | 10.7M | $601.4M | 0.5% | 2.4% | -7.4% |
| 8 | BAILLIE GIFFORD & CO | 10.0M | $561.6M | 0.5% | 2.3% | -38.0% |
| 9 | Capital World Investors | 9.5M | $533.6M | 0.1% | 2.1% | +18.4% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 8.1M | $450.6M | 0.0% | 1.8% | +2.4% |
| 11 | Caledonia (Private) Investments Pty Ltd | 5.8M | $323.9M | 11.1% | 1.3% | -19.4% |
| 12 | NORGES BANKNEW | 5.3M | $299.2M | 0.0% | 1.2% | new |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 4.8M | $270.6M | 0.0% | 1.1% | +6.5% |
| 14 | NORTHERN TRUST CORP | 4.7M | $264.6M | 0.0% | 1.1% | +23.9% |
| 15 | ROYAL LONDON ASSET MANAGEMENT LTD | 4.3M | $242.2M | 0.4% | 1% | +13.4% |
| 16 | AQR CAPITAL MANAGEMENT LLC | 4.3M | $241.4M | 0.1% | 1% | +13.8% |
| 17 | Invesco Ltd. | 4.2M | $237.3M | 0.0% | 1% | +12.8% |
| 18 | BANK OF AMERICA CORP /DE/ | 4.1M | $232.7M | 0.0% | 0.9% | +18.7% |
| 19 | Legal & General Group Plc | 3.8M | $213.1M | 0.0% | 0.9% | +13.0% |
| 20 | Amundi | 3.7M | $208.8M | 0.1% | 0.8% | +20.6% |
| 21 | VICTORY CAPITAL MANAGEMENT INC | 3.7M | $206.5M | 0.1% | 0.8% | -4.4% |
| 22 | Patient Capital Management, LLC | 3.6M | $201.8M | 6.6% | 0.8% | -1.2% |
| 23 | UBS Group AG | 3.1M | $176.2M | 0.0% | 0.7% | +73.5% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.1M | $172.9M | 0.0% | 0.7% | +1.8% |
| 25 | TWO SIGMA INVESTMENTS, LP | 2.9M | $163.7M | 0.1% | 0.7% | +29.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.